Finance

Lists
ZBIO:NASDAQ
Zenas Biopharma Inc
$25.43
+1.07%
(+0.27) 1D
Oct 14, 10:03:25 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBIO...
Open
$24.82
High
$26.49
Low
$24.39
Mkt. cap
1.66B
Avg. vol.
682.64K
Volume
16.67K
52-wk high
$44.60
52-wk low
$13.50
EPS
-$8.97
Shares outstanding
65.18M
No. of employees
167
Open
$24.82
High
$26.49
Low
$24.39
Mkt. cap
1.66B
Avg. vol.
682.64K
Volume
16.67K
52-wk high
$44.60
52-wk low
$13.50
EPS
-$8.97
Shares outstanding
65.18M
No. of employees
167
News stories
From web sources and news partners
About Zenas Biopharma Inc
CEO-
Employees167
Founded2019
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitezenasbio.com
Analyst ratings
Based on 5 analysts giving stock ratings to ZBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ZBIO in the last 3 months.
Highest
Current $25.43
$55.00 (+116.28%)
Average
$44.80 (+76.17%)
Lowest
$32.00 (+25.84%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Wedbush
Buy
Maintained
$45.00
+77%
10/13/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$44.00
+73%
10/13/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$48.00
+88.8%
10/12/2026
Martin Fan
Wedbush
Buy
Maintained
$45.00
+77%
09/30/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
$32.00
+25.8%
08/17/2026
David Nierengarten
Wedbush
Buy
Maintained
$45.00
+77%
08/14/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$55.00
+116.3%
08/13/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$44.00
+73%
06/08/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$55.00
+116.3%
03/17/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
-$1.77 / -$0.75
-134.44%miss
Revenue / Est. (USD)
1.00M / 15.00M
-93.33%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
1.00M
Cost of goods sold
34.40M
55.72M
60.44M
62.91M
Cost of revenue
34.40M
55.72M
60.44M
62.91M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.18M
15.59M
16.91M
15.75M
Operating expense
13.18M
15.59M
16.91M
15.75M
Total operating expenses
47.58M
71.31M
77.35M
78.66M
Operating income
-47.58M
-71.31M
-77.35M
-77.66M
Other non operating income
1.08M
-7.48M
-24.00K
16.00K
EBT including unusual items
-51.50M
-240.34M
-80.99M
-111.34M
EBT excluding unusual items
-46.50M
-73.66M
-80.99M
-81.34M
Income tax expense
-
106.00K
-
114.00K
Effective tax rate
-
-0.04%
-
-0.10%
Other operating expenses
-
-
-
-
Net income
-51.50M
-240.44M
-80.99M
-111.46M
Net profit margin
-
-
-
-11,145.60%
Earnings per share
-1.22
-1.39
-1.46
-1.77
Interest and investment income
-
12.15M
3.02M
6.60M
Interest expense
-
-7.33M
-6.63M
-10.30M
Net interest expenses
-
4.82M
-3.61M
-3.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
-47.57M
-71.30M
-77.34M
-77.66M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps